Madrigal outlays $1bn for Arrowhead’s siRNA MASH asset

siRNA MASH assetPositive

AI Analysis

Summary

Madrigal Pharmaceuticals has acquired Arrowhead Pharmaceuticals' siRNA MASH asset for $1 billion. The transaction represents a significant move by Madrigal to expand its pipeline in the metabolic dysfunction-associated steatohepatitis space.

Outcome Details

Madrigal Pharmaceuticals acquires Arrowhead Pharmaceuticals' siRNA MASH asset for $1 billion

Importance:7/10

Sentiment:

0.60

M&AacquisitionsiRNAMASHasset purchase

Related Companies

$ARWR

Read the original article

Published by yahoo_finance on May 5, 2026 3:53 PM

Read Original